TGTX Stock Forecast: TG Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$63
−2.45% on the day

The 8 Wall Street analysts covering TG Therapeutics, Inc. hold a median 12-month price target of $75 — +18.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 78 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$9.8B
Ticker Nerd rank
78/ 100
Median analyst target
$75
Analysts covering
8
Revenue$240.3M+70.3% y/y
Operating income$21.7M
Net income$7.8M
Free cash flow$39.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
+16.1%
YTD
+112.3%
1Y
+107.8%
From 52W high
−4.3%
From 52W low
+134.9%
$27
$66
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores TG Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
78/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Value
96
Volatility
94
Quality
90
Revisions
77
Growth
51
Issuance
35
Accruals
13

Momentum (97): The shares have been drifting up relative to others.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Jan 26Apr 26Jul 26Oct 26TGTXHigh $86Median $75Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7
Buy
0
Hold
1
Sell
$21
Low
$75
Median
$86
High

The green dot is the last close — the median target sits +18.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Nov 2026Evercore ISI GroupMaintainsOutperform$73 → $71
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$78
7 Aug 2026JP MorganMaintainsOverweight$65 → $72
27 July 2026B. Riley SecuritiesMaintainsBuy$55 → $86
13 July 2026HC Wainwright & Co.MaintainsBuy$70 → $77
7 July 2026B of A SecuritiesMaintainsUnderperform$17 → $20
6 July 2026HC Wainwright & Co.ReiteratesBuy$70
27 May 2026HC Wainwright & Co.ReiteratesBuy—
6 May 2026HC Wainwright & Co.MaintainsBuy—
2 Feb 2026JP MorganMaintainsOverweight—
15 Jan 2026Goldman SachsMaintainsNeutral—
3 Nov 2025JP MorganMaintainsOverweight—
6 Oct 2025HC Wainwright & Co.AssumesBuy$60
17 Sept 2025B. Riley SecuritiesMaintainsBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Jan 2025HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024JP MorganMaintainsOverweight—
5 Nov 2024Goldman SachsMaintainsNeutral—
5 Nov 2024HC Wainwright & Co.MaintainsBuy—
29 Oct 2024TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TGTX.

Market Radar

This page is one stock. Monday covers all of them.

TGTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TGTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, TG Therapeutics, Inc. returned +107.8% against +6.9% for the S&P 500, dividends included.

TGTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26TGTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−2.7%
Analysts raising
0
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
97.4×

Cheaper than 8% of US stocks

Price / sales
11.0×

Cheaper than 11% of US stocks

Price / book
16.0×

Cheaper than 4% of US stocks

EV / EBITDA
48.4×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−85.8%

Higher than 4% of US stocks

Gross margin
82.9%

Higher than 93% of US stocks

Operating margin
21.5%

Higher than 81% of US stocks

Net margin
—
Returns & dividend
Return on equity
18.0%

Higher than 79% of US stocks

Return on assets
9.2%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TG Therapeutics, Inc. has a market value of $9.8B and an enterprise value of $9.3B.

  • Revenue in the twelve months to 30 June 2026: $799.5M. The latest quarter grew 70.3% year on year.

  • Net income over the same four quarters: $441.5M, a 55.2% net margin.

  • Diluted earnings per share, trailing twelve months: $2.74.

  • Free cash flow in the twelve months to 30 June 2026: $17.4M.

  • TG Therapeutics, Inc. spent $178.2M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 153.1M.

  • Trailing P/E: 97.4×; forward P/E: 25.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • TG Therapeutics, Inc. employs 399 people — $2.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

TGTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TGTXTG Therapeutics, Inc.$9.8B78
HALOHalozyme Therapeutics, Inc.$10.4B96
KYMRKymera Therapeutics, Inc.$9.6B65
KRYSKrystal Biotech, Inc.$9.1B83
TECHBio-Techne Corp.$11.3B96
PCVXVaxcyte, Inc.$8.7B46
MDGLMadrigal Pharmaceuticals, Inc.$8.7B79

Take a look at TGTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own TG Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TGTX

What is the TGTX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering TG Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $21 to $86. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TGTX stock a buy right now?

Of the 8 analysts covering TG Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks TG Therapeutics, Inc. 78 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TGTX?

As at 21 Nov 2026, TG Therapeutics, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will TGTX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +18.5% from the last close, and Ticker Nerd's factor model ranks TG Therapeutics, Inc. 78 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TGTX stock forecast for 2030?

No analyst covering TG Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $86 over the next 12 months.

How has TGTX stock performed over the past year?

TG Therapeutics, Inc. returned +107.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TG Therapeutics, Inc. do?

TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease.

Company

About TG Therapeutics, Inc.

TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease. TG Therapeutics also advances a broader pipeline of therapies, including subcutaneous and intravenous formulations of ublituximab, along with investigational programs such as Azer-cel. Its portfolio is centered on immune-related and hematologic conditions, reflecting a business model built around specialty medicines that target B-cell activity. TG Therapeutics serves patients and healthcare providers in the United States and internationally through its marketed products and development-stage candidates.

CEO Mr. Michael S. Weiss Esq., J.D. · 399 employees · United States · https://www.tgtherapeutics.com